New antibody aims to help lungs heal faster in severe breathing emergencies
NCT ID NCT05938036
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 29 times
Summary
This study tests a single dose of an experimental antibody called ALT-100 in 15 adults hospitalized with moderate to severe acute respiratory distress syndrome (ARDS), a life-threatening lung condition. The main goal is to check safety and side effects, while also seeing if it reduces the need for a breathing machine and shortens hospital stays. Participants are randomly assigned to receive either the drug or a placebo, and neither they nor their doctors know which they get.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Banner University of Arizona
Tucson, Arizona, 85721, United States
Conditions
Explore the condition pages connected to this study.